- Home
- TRTX vs PLRX Comparison
TRTX vs PLRX Comparison
Compare TRTX & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRTX
- PLRX
- Stock Information
- Founded
- TRTX 2014
- PLRX 2015
- Country
- TRTX United States
- PLRX United States
- Employees
- TRTX N/A
- PLRX N/A
- Industry
- TRTX Real Estate Investment Trusts
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- TRTX Real Estate
- PLRX Health Care
- Exchange
- TRTX Nasdaq
- PLRX Nasdaq
- Market Cap
- TRTX 718.6M
- PLRX 641.5M
- IPO Year
- TRTX 2017
- PLRX 2020
- Fundamental
- Price
- TRTX $8.77
- PLRX $13.21
- Analyst Decision
- TRTX Buy
- PLRX Strong Buy
- Analyst Count
- TRTX 6
- PLRX 7
- Target Price
- TRTX $9.08
- PLRX $40.50
- AVG Volume (30 Days)
- TRTX 647.0K
- PLRX 591.6K
- Earning Date
- TRTX 02-18-2025
- PLRX 11-07-2024
- Dividend Yield
- TRTX 10.95%
- PLRX N/A
- EPS Growth
- TRTX N/A
- PLRX N/A
- EPS
- TRTX 0.69
- PLRX N/A
- Revenue
- TRTX $133,089,000.00
- PLRX N/A
- Revenue This Year
- TRTX N/A
- PLRX N/A
- Revenue Next Year
- TRTX $1.96
- PLRX N/A
- P/E Ratio
- TRTX $12.65
- PLRX N/A
- Revenue Growth
- TRTX N/A
- PLRX N/A
- 52 Week Low
- TRTX $5.12
- PLRX $10.22
- 52 Week High
- TRTX $9.66
- PLRX $19.62
- Technical
- Relative Strength Index (RSI)
- TRTX 46.02
- PLRX 43.89
- Support Level
- TRTX $8.48
- PLRX $13.14
- Resistance Level
- TRTX $9.19
- PLRX $15.00
- Average True Range (ATR)
- TRTX 0.22
- PLRX 0.81
- MACD
- TRTX -0.06
- PLRX -0.12
- Stochastic Oscillator
- TRTX 40.28
- PLRX 5.13
About TRTX TPG RE Finance Trust Inc.
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating rate first mortgage loans that are secured by high quality commercial real estate properties undergoing some form of transition and value creation.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.